Drug resistance in cancers of childhood. Part I - Proteins associated with drug resistance;Lekooporność w nowotworach wieku dzieciecego. Cześć I - Białka zwiazane z lekoopornościa

Onkologia Polska

Volumn 8, Issue 2, 2005, Pages 57-61

  Zaremba, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

ABC transporters; Cancers; Chemotherapy; Drug resistance

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CELL PROTEIN; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; VINBLASTINE; VINCRISTINE;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROTECTION; CHILD; CHILDHOOD CANCER; CYTOPLASM; DRUG TRANSPORT; HUMAN; INTRACELLULAR TRANSPORT; MULTIDRUG RESISTANCE; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; TREATMENT FAILURE;

EID: 25444434413     PISSN: 15056732     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Giacone G., Pinedo H.M.: Drug resistance. Oncologist 1996, 1, 82-87.
2. Tannock I.F.: Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001, 20, 123-132.
3. Goldie J.H: Drug resistance in cancer: a perspective. Cancer Metastasis Rev. 2001, 20, 63-68.
4. Stavrovskaya A.A.: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc.) 2000, 65, 95-106.
5. Lehnert M.: Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer 1996, 32A, 912-920.
6. Perwaiz Iqbal M: Mechanisms of drug resistance in cancer cells. Pak. J. Med. Sci 2003, 19, 118-127.
7. Gottesmann M.M.: Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53, 615-627.
8. Townsend D.M., Tew K.D.: The role of glutathione-S-transterase in anticancer drug resistance. Oncogene 2003, 22, 7369-7375.
9. Longley D.B., Johnston P.G.: Molecular mechanisms of drug resistance. J. Pathol. 2005, 205, 275-292.
10. Longo-Sorbello G.S., Bertino J.R.: Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 2001, 86, 121-127.
11. Gerson S.L.: Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 2002, 20, 2388-2399.
12. Kaufmann S.H., Vaux D.L.: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 2003, 22, 7414-7430.
13. Locher K.P.: Structure and mechanism of ABC transporters. Curr. Opin. Struct. Biol. 2004, 14, 426-431.
14. Litman T., Druley T.E., Stein W.D., Bates S.E.: From MDR to MXR: new understanding of multidrug resistance systems, their properities and clinical significance. Cell. Mol. Life Sci. 2001, 58, 931-959.
15. Gottesman M.M., Fojo T., Bates S.E.: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
16. Leonard G.D., Fojo T., Bates S.E.: The role of ABC transporters in clinical practice. Oncologist 2003, 8, 411-424.
17. Fardel O., Lecureur V., Guillouzo A.: The P-glycoprotein multidrug transporter. Gen. Pharmacol. 1996, 27, 1283-1291.
18. Lum B.L., Gosland M.P.: MDR expression in normal tissues. Pharmacologric implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am. 1995, 9, 319-336.
19. Cole S.P., Bhardwaj G., Gerlach J.H. i wsp.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
20. Kruh G.D., Zeng H., Rea P.A. i wsp.: MRP subfamily transporters and resistance to anticancer agents. J. Bioenerg. Biomembr. 2001, 33, 493-501.
21. Lautier D., Canitrot Y., Deeley R.G., Cole S.P.C.: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem. Pharmacol. 1996, 52, 967-977.
22. Kruch G.D., Belinsky M.G.: The MRP family of drug efflux pumps. Oncogene. 2003, 22, 7537-7552.
23. Borst P., Evers R., Kool M., Wijnholds J.: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 2000, 92, 1295-1302.
24. Ross D.D.: Novel mechanisms of drug resistance in leukemia. Leukemia 2000, 14, 467-473.
25. Doyle L.A., Ross D.D.: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22, 7340-7358.
26. Abbott B.L.: ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol. Oncol. 2003, 21, 115-130.
27. Izquierdo M.A., Scheffer G.L., Flens M.J. i wsp.: Major vault protein LRP-related multidrug resistance. Eur. J. Cancer 1996, 32A, 979-984.
28. Mossink M.H., van Zon A., Scheper R.J. i wsp.: Vaults: a ribonuclein particle involved in drug resistance? Oncogene 2003, 22, 7458-7467.
29. Sugawara O., Akiyama S., Scheper R.J., Itoyama S.: Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett. 1997, 112, 23-31.